The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Chelsea Therapeutics International, Ltd. (“Chelsea” or the “Company”) (NasdaqCM: CHTP) and other violations of state law by the board of directors of Chelsea relating to the proposed buyout of the Company by H. Lundbeck A/S (“Lundbeck”). Under the terms of the transaction, public shareholders of Chelsea would receive $6.44 in cash, and up to $1.50 per share in a Contingent Value Right, for each share of Chelsea they own. According to Yahoo! Finance, at least one analyst has set a target price for Chelsea stock at $12.00 per share. The firm’s investigation seeks to determine, among other things, whether the Company’s board of directors breached their fiduciary duties by failing to maximize shareholder value before agreeing to enter into this transaction, and whether Lundbeck is underpaying for Chelsea shares. If you currently own common stock of Chelsea and would like to learn more about the investigation being conducted by Brower Piven, without cost or obligation to you, click here: http://www.browerpiven.com/currentinvestigations.html. You may also request more information by contacting Brower Piven either by email at firstname.lastname@example.org or by telephone at (410) 415-6616. Attorneys at Brower Piven together have more than a century of experience litigating securities and other class action cases.